Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1966 2
1967 1
1968 5
1969 4
1970 8
1971 7
1972 7
1973 6
1974 8
1975 17
1976 17
1977 18
1978 9
1979 18
1980 26
1981 15
1982 21
1983 11
1984 16
1985 16
1986 12
1987 11
1988 14
1989 11
1990 12
1991 15
1992 13
1993 14
1994 15
1995 20
1996 14
1997 18
1998 26
1999 21
2000 33
2001 30
2002 38
2003 27
2004 44
2005 49
2006 50
2007 54
2008 45
2009 54
2010 76
2011 60
2012 69
2013 56
2014 58
2015 79
2016 75
2017 63
2018 51
2019 58
2020 68
2021 74
2022 81
2023 15
Text availability
Article attribute
Article type
Publication date

Search Results

1,600 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Sarsama
Page 1
Targeting MET Dysregulation in Cancer.
Recondo G, Che J, Jänne PA, Awad MM. Recondo G, et al. Cancer Discov. 2020 Jul;10(7):922-934. doi: 10.1158/2159-8290.CD-19-1446. Epub 2020 Jun 12. Cancer Discov. 2020. PMID: 32532746 Free PMC article. Review.
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.
Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, Hardin AI, Wei Z, Hong F, Bahcall M, Gokhale PC, Jänne PA. Kobayashi Y, et al. Nature. 2022 Mar;603(7900):335-342. doi: 10.1038/s41586-022-04451-4. Epub 2022 Mar 2. Nature. 2022. PMID: 35236983
Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
Lim SM, Kim CG, Lee JB, Cho BC. Lim SM, et al. Cancer Discov. 2022 Jan;12(1):16-19. doi: 10.1158/2159-8290.CD-21-1429. Cancer Discov. 2022. PMID: 35022206
HER3 is ubiquitously expressed in EGFR-mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Janne and colleagues high …
HER3 is ubiquitously expressed in EGFR-mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinas …
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
Haikala HM, Lopez T, Köhler J, Eser PO, Xu M, Zeng Q, Teceno TJ, Ngo K, Zhao Y, Ivanova EV, Bertram AA, Leeper BA, Chambers ES, Adeni AE, Taus LJ, Kuraguchi M, Kirschmeier PT, Yu C, Shiose Y, Kamai Y, Qiu Y, Paweletz CP, Gokhale PC, Jänne PA. Haikala HM, et al. Cancer Res. 2022 Jan 1;82(1):130-141. doi: 10.1158/0008-5472.CAN-21-2426. Epub 2021 Sep 21. Cancer Res. 2022. PMID: 34548332 Free PMC article.
1,600 results